In a significant move to address a pressing global health issue, the World Health Organization (WHO) has unveiled new guidelines emphasizing the importance of opioid agonist maintenance treatment (OAMT) as a vital health service. This guidance, released on December 16, 2025, aims to assist in minimizing disruptions to services that cater to individuals struggling with opioid dependence. For more details, you can access the official WHO publication here: https://www.who.int/publications/i/item/B09543.
To put this issue in perspective, it's important to note that in 2022, around 60 million individuals across the globe were reported to be using opioids non-medically. This group includes a variety of substances such as heroin, morphine, codeine, fentanyl, methadone, and tramadol.
OAMT has proven to be a cost-effective solution, significantly decreasing rates of mortality and morbidity among those affected. It also reduces non-medical opioid use, along with the transmission of viruses like HIV and hepatitis C. Additionally, OAMT contributes to lower incidences of risky behaviors, crime, and social costs while enhancing treatment retention rates and overall quality of life for patients.
The WHO firmly advocates for the broad accessibility of OAMT, urging that it should either be provided at no cost or be covered by public health insurance systems, accompanied by a suitable governance framework.
In light of these developments, the WHO is calling upon countries, healthcare planners, service providers, policymakers, and all stakeholders involved in treatment and overdose prevention programs to ensure that these life-saving services continue without interruption.
This is a crucial moment in public health, and it raises important questions: Are governments doing enough to support OAMT? What steps can be taken to improve access to these essential services? Join the discussion and share your thoughts.
